Venture fund & syndicate investing in transformational technologies that elevate
mental health & wellness: psychedelic medicine, neurotechnology, precision psychiatry and digital therapeutics.
mental health & wellness: psychedelic medicine, neurotechnology, precision psychiatry and digital therapeutics.
Location: United States, California, San Francisco
Employees: 1-10
Founded date: 2020
Investors 1
| Date | Name | Website |
| - | Ambush Cap... | ambush.cap... |
Mentions in press and media 10
| Date | Title | Description |
| 16.08.2026 | Remepy Secures $36 Million Series A, Propelling Hybrid Drug Innovation | Remepy, a New York biotech, secured $36 million in Series A funding. Total raised hits $62 million. O.G. Venture Partners and M Ventures led the round. Funds drive Hybrid Drug development and Parkinson's program, Hybridopa, into global Phas... |
| 12.08.2026 | Remepy Raises $36M in Series A Funding | Remepy, a NYC-based provider of a platform for hybrid drugs that combine prescription medicines with personalized, AI-driven therapeutic apps, raised $36M in Series A funding. The round was led by O.G. Venture Partners and M Ventures, with ... |
| 20.11.2024 | Jimini Health: A New Dawn for Mental Health with AI Integration | In the bustling landscape of digital health, a new player has emerged, promising to reshape the way we approach mental healthcare. Jimini Health, a New York-based startup, has launched with a robust $8 million in pre-seed funding. This infu... |
| 19.11.2024 | Jimini Health Launches with $8M for AI Therapist Assistant, Sage | Jimini Health co-founders Luis Voloch, Mark Jacobstein, and Sahil Sud. Photo credit: Jimini Health. What You Should Know: – Jimini Health, a digital health company reimagining mental healthcare, has announced its launch with $8 million in p... |
| 26.01.2024 | Motif Neurotech Raises $18.75M for Implantable Device for Treatment-Resistant Depression | What You Should Know: – Motif Neurotech, a pioneer in minimally-invasive bioelectronics for mental health, announced today an impressive $18.75 million Series A funding round. Led by Arboretum Ventures, the investment saw participation from... |
| 12.05.2023 | 11 investors predict a colorful, if difficult, future for psychedelic startups | How far has the psychedelics medicines industry come over the past 12 months? Well, it depends on where you look. If you look at the stock market, the view isn’t very good: the charts are all down and in the red, and all you can see are psy... |
| 16.03.2023 | Meet the top 14 VCs who've bet the most cash on turning psychedelics into medical treatments | Sean McLintock, Sonia Weiss Pick, Michael Sobeck, and Nikolay Tretiyakov Neo Kuma Ventures, WPSS.bio, Ambria Capital, Leafly Tunnel, Tyler Le/Insider This story is available exclusively to Insider subscribers. Become an Insider and start re... |
| 04.05.2022 | Psychedelics startups are on a long journey to consumer markets, but these 5 VCs are taking the ride | “Like a pressure cooker, COVID blew the lid off what was a simmering mental health crisis for over a decade,” VC Tim Schlidt told TechCrunch. According to the World Health Organization, the global prevalence of anxiety and depression increa... |
| 08.01.2022 | Venture water, biotech investing and 2021’s carnage | Welcome to The TechCrunch Exchange, a weekly startups-and-markets newsletter. It’s inspired by the daily TechCrunch+ column where it gets its name. Want it in your inbox every Saturday? Sign up here. Welcome back to the working world, frien... |
| - | PsyMed Ventures’ Greg Kubin on Investing in Psychedelics | Greg Kubin thinks that the hippies had it right all along. “They adopted certain healthy eating practices, veganism. They created the music festival. They used psychedelics, cannabis. They brought a lot of Eastern traditions to the West,” h... |